Get latest articles and stories on World at LatestLY. Corbevax, a 'recombinant protein sub-unit' vaccine developed by Texas-based vaccine developers, was recently granted emergency approval by the Indian government and will be manufactured by the Hyderabad-based company Biological E, one of the world's largest vaccine manufacturers. World News | Discussions Underway for WHO Approval for Corbevax COVID-19 Vaccine, Says Developer.
Corbevax, a recombinant protein sub-unit vaccine developed by Texas-based vaccine developers, was recently granted emergency approval by the Indian government
Corbevax, a recombinant protein sub-unit vaccine developed by Texas-based vaccine developers, was recently granted emergency approval by the Indian government
Corbevax, a 'recombinant protein sub-unit' vaccine developed by Texas-based vaccine developers, was recently granted emergency approval by the Indian government and will be manufactured by the Hyderabad-based company Biological E, one of the world's largest vaccine manufacturers.
Corbevax, a recombinant protein sub-unit vaccine developed by Texas-based vaccine developers, was recently granted emergency approval by the Indian government
FacebookTwitterEmail
Peter Hotez, co-director of Texas Children's Hospitals Center for Vaccine Development, poses for a photograph outside the lab Thursday, June 18, 2020, in Houston.Yi-Chin Lee, Houston Chronicle / Staff photographer
New vaccines are on the horizon — but is it too late to blunt the pandemic’s winter surge? Might Houston fare better than the rest of Texas? And why could a traditional-method vaccine be better for kids?
To answer these questions, we once again check in with vaccine researcher Peter Hotez, one of the country’s best explainers of COVID-19 science. He’s a professor and dean of the National School of Tropical Medicine at Baylor College of Medicine, and he co-directs the Texas Children’s Hospital Center for Vaccine Development, where his lab team is developing COVID-19 vaccines.
FacebookTwitterEmail
Peter Hotez, co-director of Texas Children's Hospitals Center for Vaccine Development, poses for a photograph outside the lab Thursday, June 18, 2020, in Houston.Yi-Chin Lee, Houston Chronicle / Staff photographer
New vaccines are on the horizon — but is it too late to blunt the pandemic’s winter surge? Might Houston fare better than the rest of Texas? And why could a traditional-method vaccine be better for kids?
To answer these questions, we once again check in with vaccine researcher Peter Hotez, one of the country’s best explainers of COVID-19 science. He’s a professor and dean of the National School of Tropical Medicine at Baylor College of Medicine, and he co-directs the Texas Children’s Hospital Center for Vaccine Development, where his lab team is developing COVID-19 vaccines.